FOUNDATION FOR ANGELMAN SYNDROME T… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2008

Legal Domicile

Principal Officer

RYAN JACOB

Phone

8667830078

Tax Period

2024-01-01 to 2024-12-31

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, founded in 2008, is a community nonprofit in the Medical Research sector that reported $5.4M in total revenue in fiscal year 2024. Revenue decreased 17% compared to the prior year. Expenses of $10.4M exceeded revenue, resulting in a 93% operating deficit.

Mission

ANGELMAN SYNDROME (AS) IS A NEURODEVELOPMENTAL DISORDER CHARACTERIZED BY GLOBAL DEVELOPMENT DELAYS AND SEVERE SPEECH IMPAIRMENT. A FEW INDIVIDUALS WITH AS DEVELOP FUNCTIONAL SPEECH, BUT MOST COMMUNICATE THROUGH A MIXTURE OF GESTURES, EYE GAZE, ADAPTED SIGN LANGUAGE AND AUGUMENTATIVE COMMUNICATION DEVICES. INDIVIDUALS WITH AS HAVE DEVELOPMENT DELAY AND INTELLECTUAL DISABILITIES. CURRENT RESEARCH SUGGESTS THAT NEURONAL DEVELOPMENT OCCURS CORRECTLY IN AS, BUT NEURONAL FUNCTIONING IS IMPAIRED. THIS NEURONAL IMPAIRMENT IMPACTS THE INDIVIDUAL'S ABILITY TO LEARN IN THAT SKILLS ARE ACQUIRED LESS RAPIDLY THAN IN AGE-MATCHED PEERS. THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS IS AN ORGANIZATION OF FAMILIES AND PROFESSIONALS DEDICATED TO FINDING A CURE FOR AS AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGRESSIVE RESEARCH AGENDA, EDUCATION, ADVOCACY, AND COMMUNITY SUPPORT. FAST IS COMMITTED TO ASSISTING INDIVIDUALS LIVING WITH AS TO REALIZE THEIR FULL POTENTIAL AND QUALITY OF LIFE.

Program Service Accomplishments

Program 1

Expenses: $3,698,573

FAST'S PRIMARY GOAL IS TO ADVANCE RESEARCH LEADING TO A CURE FOR AS IN THE FORM OF PROVIDING GRANTS TO UNIVERSITIES TO PERFORM RESEARCH AND TESTING.

Program 2

Expenses: $5,532,984

AS IS A RARE DISORDER. THE COMMUNITY OF PARENTS AND CAREGIVERS OF INDIVIDUALS WITH AS RELY HEAVILY ON SOCIAL NETWORKING TO BECOME INFORMED AND SEEK ADVICE AND GUIDANCE ON THE CHALLENGES WHICH THE...

AS IS A RARE DISORDER. THE COMMUNITY OF PARENTS AND CAREGIVERS OF INDIVIDUALS WITH AS RELY HEAVILY ON SOCIAL NETWORKING TO BECOME INFORMED AND SEEK ADVICE AND GUIDANCE ON THE CHALLENGES WHICH THE DISORDER PRESENTS. IT IS ONE OF FAST'S OBJECTIVES TO EDUCATE, SUPPORT, AND STRENGTHEN THIS COMMUNITY.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $3,723,744

Program Service Revenue $0

Investment Income $1,677,094

Other Revenue $-12,578

TOTAL REVENUE $5,388,260

Expense Breakdown

Grants Paid $3,698,573

Salaries & Benefits $2,926,752

Fundraising Expenses $398,605

Program Expenses $9,231,557

Other Expenses $3,766,644

TOTAL EXPENSES $10,391,969

Year-over-Year Comparison

	2024	2023	Change
Revenue	$5,388,260	$6,525,815	-0.2%
Expenses	$10,391,969	$23,229,158	-0.6%
Net Income	$-5,003,709	$-16,703,343	-0.7%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

291

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$1,483,711

Total Directors

$509,945

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
RYAN JACOB	CHAIRPERSON	18.00	Officer Director	$0	$0	$0
MICHAEL HANRAHAN	VICE CHAIRPERSON AND TR	10.00	Officer Director	$0	$0	$0
GUY SHAPIRAL	TRESURER	15.00	Officer Director	$0	$0	$0
AMELIA BEATTY	SECRETARY	15.00	Director	$0	$0	$0
KARLY WARNER	DIRECTOR	5.00	Director	$0	$0	$0
JOHN SCHLUETER	DIRECTOR	15.00	Director	$0	$0	$0
KELLY DAVID	DIRECTOR	10.00	Officer Director	$0	$0	$0
BEN O'CONNOR	DIRECTOR	5.00	Director	$0	$0	$0
ROY AZOUT	DIRECTOR	5.00	Director	$0	$0	$0
LAUREN HOFFER	DIRECTOR	5.00	Director	$0	$0	$0
NORA XU	DIRECTOR	5.00	Director	$0	$0	$0
ALLYSON BERENT	CHIEF SCIENCE OFFICER	2.00	Officer Director	$0	$0	$509,945
RYAN K FISCHER	CHIEF OPERATING OFICER	40.00	Officer	$286,130	$0	$286,130
ALANA NEWHOUSE	PRESIDENT/CEO	40.00	Officer	$245,000	$0	$245,000
KENA PEARSON	CHIEF FINANCIAL OFFICER	40.00	Officer	$232,568	$0	$232,568
MICHELE GOLOMBUSKI	CHIEF DEVELOPMENT OFFICER	40.00	Officer	$210,068	$0	$210,068

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$5,388,260	$10,391,969	$44,915,881	$-5,003,709
2023	$6,525,815	$23,229,158	$58,430,242	$-16,703,343
2022	$52,477,819	$8,933,021	$63,075,354	$43,544,798
2021	$3,977,487	$5,835,365	$17,749,994	$-1,857,878
2020	$9,357,654	$3,052,395	$18,338,531	$6,305,259
2019	$5,739,183	$4,561,879	$12,005,469	$1,177,304
2018	$5,274,393	$2,948,068	$8,901,866	$2,326,325

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS